jarmoluk / Pixabay
Phase 3 Childhood-Onset Growth Hormone Deficiency Trial Continues Enrollment
Aeterna Zentaris’s ongoing DETECT trial is evaluating the drug macimorelin (tradename Macrilen™) for childhood-onset growth hormone deficiency (CGHD). As recently announced in an article published by GlobeNewsWire, the study (AEZS-130-PO2),…
Continue Reading
Phase 3 Childhood-Onset Growth Hormone Deficiency Trial Continues Enrollment
